+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Fatty Liver Disease - Pipeline Review, H2 2015

  • ID: 3448651
  • Report
  • September 2015
  • 148 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • DURECT Corporation
  • Gilead Sciences, Inc.
  • Nimbus Therapeutics, LLC
  • Sancilio & Company, Inc.
  • Viking Therapeutics, Inc.
  • MORE
Fatty Liver Disease - Pipeline Review, H2 2015

Summary

The report ‘Fatty Liver Disease - Pipeline Review, H2 2015’, provides an overview of the Fatty Liver Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

Loading
LOADING...

3 of 5

FEATURED COMPANIES

  • ChemoCentryx, Inc.
  • DURECT Corporation
  • Gilead Sciences, Inc.
  • Nimbus Therapeutics, LLC
  • Sancilio & Company, Inc.
  • Viking Therapeutics, Inc.
  • MORE
List of Tables

List of Figures

Introduction

REPORT COVERAGE

Fatty Liver Disease Overview

Therapeutics Development

Pipeline Products for Fatty Liver Disease - Overview

Pipeline Products for Fatty Liver Disease - Comparative Analysis

Fatty Liver Disease - Therapeutics under Development by Companies

Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes

Fatty Liver Disease - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Fatty Liver Disease - Products under Development by Companies

Fatty Liver Disease - Products under Investigation by Universities/Institutes

Fatty Liver Disease - Companies Involved in Therapeutics Development

Arisaph Pharmaceuticals, Inc.

ChemoCentryx, Inc.

Conatus Pharmaceuticals Inc.

Daewoong Pharmaceutical Co., Ltd.

Dimerix Bioscience Pty Ltd

Dr. Falk Pharma GmbH

DURECT Corporation

Galmed International Ltd.

Generon (Shanghai) Corporation Ltd.

Genovate Biotechnology Co., LTD.

Gilead Sciences, Inc.

Huons Co., Ltd.

Kyorin Pharmaceutical Co., Ltd.

Metabolic Solutions Development Company, LLC

Nimbus Therapeutics, LLC

Novartis AG

Protalix BioTherapeutics, Inc.

Raptor Pharmaceuticals Corp.

Sancilio & Company, Inc.

TCM Biotech International Corp

Tobira Therapeutics, Inc.

Verva Pharmaceuticals Limited

Viking Therapeutics, Inc.

Zafgen Inc.

Zydus Cadila Healthcare Limited

Fatty Liver Disease - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

Aramchol - Drug Profile

ARI-3037MO - Drug Profile

C-10 - Drug Profile

CCX-872 - Drug Profile

cenicriviroc mesylate - Drug Profile

cysteamine DR - Drug Profile

DMX-300 - Drug Profile

Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile

DUR-928 - Drug Profile

DWP-10292 - Drug Profile

emricasan - Drug Profile

etanercept biosimilar - Drug Profile

F-652 - Drug Profile

HU-002 - Drug Profile

KDT-501 - Drug Profile

MAT-8800 - Drug Profile

MB-12066 - Drug Profile

methazolamide - Drug Profile

MN-002 - Drug Profile

MSDC-0602 - Drug Profile

MT-2 - Drug Profile

NDI-010976 - Drug Profile

norursodeoxycholic acid - Drug Profile

oltipraz - Drug Profile

PCBB-7 - Drug Profile

pradigastat sodium - Drug Profile

Px-102 - Drug Profile

Px-103 - Drug Profile

Px-104 - Drug Profile

Recombinant Protein for Atherosclerosis and Hepatic Steatosis - Drug Profile

RT-230 - Drug Profile

saroglitazar - Drug Profile

SC-410 - Drug Profile

Small Molecule for Fatty Liver Disease - Drug Profile

Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile

Small Molecule to Inhibit Them1 for Metabolic, Immunology and Gastrointestinal Diseases - Drug Profile

Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile

Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile

Synthetic Peptides for Cardiovascular, Gastrointestinal, Metabolic Disorders and Infectious Disease - Drug Profile

TCM-606F - Drug Profile

VK-2809 - Drug Profile

VVP-100-X - Drug Profile

ZGN-839 - Drug Profile

Fatty Liver Disease - Recent Pipeline Updates

Fatty Liver Disease - Dormant Projects

Fatty Liver Disease - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Fatty Liver Disease, H2 2015

Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2015

Fatty Liver Disease - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015

Fatty Liver Disease - Pipeline by ChemoCentryx, Inc., H2 2015

Fatty Liver Disease - Pipeline by Conatus Pharmaceuticals Inc., H2 2015

Fatty Liver Disease - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015

Fatty Liver Disease - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015

Fatty Liver Disease - Pipeline by Dr. Falk Pharma GmbH, H2 2015

Fatty Liver Disease - Pipeline by DURECT Corporation, H2 2015

Fatty Liver Disease - Pipeline by Galmed International Ltd., H2 2015

Fatty Liver Disease - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2015

Fatty Liver Disease - Pipeline by Genovate Biotechnology Co., LTD., H2 2015

Fatty Liver Disease - Pipeline by Gilead Sciences, Inc., H2 2015

Fatty Liver Disease - Pipeline by Huons Co., Ltd., H2 2015

Fatty Liver Disease - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015

Fatty Liver Disease - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015

Fatty Liver Disease - Pipeline by Nimbus Therapeutics, LLC, H2 2015

Fatty Liver Disease - Pipeline by Novartis AG, H2 2015

Fatty Liver Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2015

Fatty Liver Disease - Pipeline by Raptor Pharmaceuticals Corp., H2 2015

Fatty Liver Disease - Pipeline by Sancilio & Company, Inc., H2 2015

Fatty Liver Disease - Pipeline by TCM Biotech International Corp, H2 2015

Fatty Liver Disease - Pipeline by Tobira Therapeutics, Inc., H2 2015

Fatty Liver Disease - Pipeline by Verva Pharmaceuticals Limited, H2 2015

Fatty Liver Disease - Pipeline by Viking Therapeutics, Inc., H2 2015

Fatty Liver Disease - Pipeline by Zafgen Inc., H2 2015

Fatty Liver Disease - Pipeline by Zydus Cadila Healthcare Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Fatty Liver Disease Therapeutics - Recent Pipeline Updates, H2 2015

Fatty Liver Disease - Dormant Projects, H2 2015

Fatty Liver Disease - Dormant Projects (Contd..1), H2 2015

List of Figures

Number of Products under Development for Fatty Liver Disease, H2 2015

Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015
Note: Product cover images may vary from those shown
4 of 5
Arisaph Pharmaceuticals, Inc.
ChemoCentryx, Inc.
Conatus Pharmaceuticals Inc.
Daewoong Pharmaceutical Co., Ltd.
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corporation
Galmed International Ltd.
Generon (Shanghai) Corporation Ltd.
Genovate Biotechnology Co., LTD.
Gilead Sciences, Inc.
Huons Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Metabolic Solutions Development Company, LLC
Nimbus Therapeutics, LLC
Novartis AG
Protalix BioTherapeutics, Inc.
Raptor Pharmaceuticals Corp.
Sancilio & Company, Inc.
TCM Biotech International Corp
Tobira Therapeutics, Inc.
Verva Pharmaceuticals Limited
Viking Therapeutics, Inc.
Zafgen Inc.
Zydus Cadila Healthcare Limited
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll